Morris Dean Groves Jr. MD

Neurology•Austin, TX

Neurophysiology, Neurooncology

Physician

Join to View Full Profile

901 W 38th St Ste 200Austin, TX 78705
Phone+1 512-421-4100
Fax+1 512-454-4575

Education & Training

University of Texas M D Anderson Cancer CenterFellowship, Neuro-Oncology, 1996 - 1998
University of Texas Health Science Center at HoustonResidency, Neurology, 1993 - 1996
University of Texas Health Science Center at HoustonInternship, Transitional Year, 1992 - 1993
Baylor College of MedicineInternship, Transitional Year, 1986 - 1987
Baylor College of MedicineClass of 1986

Certifications & Licensure

TX State Medical License 1987 - 2020

Clinical Trials

Temozolomide Plus Thalidomide in Treating Patients With Recurrent or Progressive Brain Tumor Start of enrollment: 2000 Jun 13
Completed
Phase 2
Capecitabine and Pegylated Interferon Alfa-2a in Treating Patients With Recurrent or Progressive Brain Metastases Due to Breast Cancer Start of enrollment: 2005 Sep 01
Terminated
Phase 2
Dietary Methionine Restriction Plus Temozolomide for Recurrent GBM Start of enrollment: 2004 Aug 01
Terminated
Phase 1
RTA 744 Injection in Patients With Leptomeningeal Disease Start of enrollment: 2006 Sep 01
Terminated
Phase 1
DepoCyt Plus Temozolomide in Patients With Neoplastic Meningitis Start of enrollment: 2006 Feb 01
Terminated
Phase 1
RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer Start of enrollment: 2010 Oct 01
TERMINATED
PHASE1, PHASE2
Intrathecal Trastuzumab for Leptomeningeal Metastases in HER2+ Breast Cancer Start of enrollment: 2011 Aug 01
Completed
Phase 1, Phase 2
A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma Start of enrollment: 2011 Dec 01
Completed
Phase 2
Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib Start of enrollment: 2013 Aug 01
Completed
Phase 2
Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab Start of enrollment: 2015 Dec 10
Completed
Phase 2
A Phase 2 Study of BGJ398 in Patients With Recurrent GBM Start of enrollment: 2013 Dec 09
Completed
Phase 2
STAR Cape+BKM120 MBC With Brain Met Start of enrollment: 2014 May 29
Completed
Phase 2
Phase 2 Study to Investigate the Efficacy and Safety of Aldoxorubicin in Subjects With Glioblastoma Start of enrollment: 2014 Mar 01
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

108 citations
Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial.
Farshad Nassiri, Vikas Patil, Leeor S Yefet, Olivia Singh, Jeff Liu
Nature Medicine. 2023-06-01
35 citations
A phase I/II study of intrathecal trastuzumab in human epidermal growth factor receptor 2-positive (HER2-positive) cancer with leptomeningeal metastases: Safety, effic...
Priya U Kumthekar, Michael J Avram, Andrew B Lassman, Nancy U Lin, Eudocia Lee
Neuro-Oncology. 2023-03-14
38 citations
Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study.
Andrew B Lassman, Juan Manuel Sepúlveda-Sánchez, Timothy F Cloughesy, Miguel J Gil-Gil, Vinay K Puduvalli
Clinical Cancer Research. 2022-06-01

Press Mentions

Brain Cancer Research Takes the Lead with Head for the Cure 5KApril 26th, 2019